TS, DHFR and GARFT Expression in Non-squamous Cell Carcinoma of NSCLC and Malignant Pleural Mesothelioma Patients Treated with Pemetrexed
作者： Takeshi Hanagiri , Hidetaka Uramoto , Hidehiko Shimokawa , Takamitsu Onitsuka
DOI:
关键词: Pathology 、 Pemetrexed 、 Epidermoid carcinoma 、 Carcinoma 、 Primary tumor 、 Lung cancer 、 Cancer 、 Thymidylate synthase 、 Cancer research 、 Medicine 、 Mesothelioma
摘要: Background Recently, pemetrexed (PEM), a new generation antifolate, has been used for the treatment of patients with advanced non-squamous cell carcinoma (SQ) non-small lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). However, no useful markers selecting appropriate candidates exist at present. Materials methods Tumor specimens were collected from 5 non-SQ 8 MPM who underwent surgery received PEM. Real-time PCR immunohistochemical (IHC) staining primary tumor to analyze mRNA protein expressions thymidylate synthase (TS)/dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyltransferase (GARFT), compare expression status clinical outcomes. Results TS, DHFR, GARFT levels had median value 2.39, 1.70, 1.40 in samples NSCLC patients. The TS DHFR mean total score 2 4 5.55, 3.73, 3.52 1 3 No significant correlation was identified between TS/DPD/GARFT response treated Conclusion may not be predicting Japanese MPM. Further investigations are necessary order develop biomarkers determine benefits PEM treatment.
参考文章(25)
E A Rayl, K A Shackelford, L L Habeck, V F Patel, L G Mendelsohn, V J Chen, S B Gates, R M Schultz, M Ratnam, J R Bewley, S L Andis, W C MacKellar, D J Soose, B A Moroson, W Kohler, L S Gossett, G P Beardsley, C Shih, LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes Cancer Research. ,vol. 57, pp. 1116- 1123 ,(1997)
Takamitsu Onitsuka, Hidetaka Uramoto, Naohiro Nose, Mitsuhiro Takenoyama, Takeshi Hanagiri, Kenji Sugio, Kosei Yasumoto, Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status Lung Cancer. ,vol. 68, pp. 198- 203 ,(2010) , 10.1016/J.LUNGCAN.2009.05.022
JP Van Meerbeeck, Paul Baas, Channa Debruyne, EF Smit, RJ Van Klaveren, D Galdermans, MA Lentz, C Manegold, Giuseppe Giaccone, EORTC Lung Cancer Group, A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. European Journal of Cancer. ,vol. 38, pp. 779- 783 ,(2002) , 10.1016/S0959-8049(01)00428-2
Paolo Ceppi, Marco Volante, Silvia Saviozzi, Ida Rapa, Silvia Novello, Alberto Cambieri, Marco Lo Iacono, Susanna Cappia, Mauro Papotti, Giorgio V. Scagliotti, Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase Cancer. ,vol. 107, pp. 1589- 1596 ,(2006) , 10.1002/CNCR.22208
M M Moasser, Targeting the Function of the HER2 Oncogene in Human Cancer Therapeutics Oncogene. ,vol. 26, pp. 6577- 6592 ,(2007) , 10.1038/SJ.ONC.1210478
Hidetaka Uramoto, Kenji Sugio, Tsunehiro Oyama, Kenji Ono, Masakazu Sugaya, Takashi Yoshimatsu, Takeshi Hanagiri, Masaru Morita, Kosei Yasumoto, Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer. ,vol. 51, pp. 71- 77 ,(2006) , 10.1016/J.LUNGCAN.2005.08.006
Nasser H. Hanna, Second-Line Chemotherapy for Non–Small-Cell Lung Cancer: Recent Data with Pemetrexed Clinical Lung Cancer. ,vol. 5, pp. S75- S79 ,(2004) , 10.3816/CLC.2004.S.007
Masakazu Toi, Tadashi Ikeda, Futoshi Akiyama, Masafumi Kurosumi, Hitoshi Tsuda, Goi Sakamoto, Osahiko Abe, Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy. International Journal of Oncology. ,vol. 31, pp. 899- 906 ,(2007) , 10.3892/IJO.31.4.899
H Uramoto, T Mitsudomi, Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? British Journal of Cancer. ,vol. 96, pp. 857- 863 ,(2007) , 10.1038/SJ.BJC.6603665
Takamitsu Onitsuka, Hidetaka Uramoto, Kenji Ono, Mitsuhiro Takenoyama, Takeshi Hanagiri, Tsunehiro Oyama, Hiroto Izumi, Kimitoshi Kohno, Kosei Yasumoto, Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. Journal of Thoracic Oncology. ,vol. 5, pp. 591- 596 ,(2010) , 10.1097/JTO.0B013E3181D0A4DB